S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
OTCMKTS:ATRX

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

$0.01
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.0137
$0.0137
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.60
Volume
10,080 shs
Average Volume
78,403 shs
Market Capitalization
$151,782.30
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ATRX stock logo

About Adhera Therapeutics Stock (OTCMKTS:ATRX)

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

ATRX Stock Price History

ATRX Stock News Headlines

Adhera Therapeutics Inc (ATRX)
ATRX Adhera Therapeutics, Inc.
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Adhera Therapeutics, Inc. (ATRX)
CGTX Cognition Therapeutics, Inc.
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Adhera Therapeutics Announces CEO, Senior...
5 Penny Stocks with Upcoming Growth Catalysts
See More Headlines
Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ATRX
Employees
2
Year Founded
N/A

Profitability

Net Income
$-2,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($7.02) per share

Miscellaneous

Free Float
7,955,000
Market Cap
$110,800.00
Optionable
Not Optionable
Beta
-0.11
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Andrew Albert Kucharchuk M.B.A. (Age 43)
    Vice Chairman, COO, Acting CFO & Chief Business Officer
    Comp: $285k

ATRX Stock Analysis - Frequently Asked Questions

How have ATRX shares performed in 2024?

Adhera Therapeutics' stock was trading at $0.03 at the beginning of the year. Since then, ATRX shares have decreased by 54.3% and is now trading at $0.0137.
View the best growth stocks for 2024 here
.

Are investors shorting Adhera Therapeutics?

Adhera Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 100 shares, a drop of 95.0% from the February 29th total of 2,000 shares. Based on an average trading volume of 220,800 shares, the days-to-cover ratio is presently 0.0 days.
View Adhera Therapeutics' Short Interest
.

When did Adhera Therapeutics' stock split?

Adhera Therapeutics shares reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Adhera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

How do I buy shares of Adhera Therapeutics?

Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ATRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners